MOLLY GILMORE: Open Payments
NPI 1144848524 · OVERLAND PARK, KS. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$536 in 28 payments from 15 companies in 2025. Trend: 2023 $0 · 2024 $0 · 2025 $536
Food & beverage: $536
| Company | Payments | Amount |
|---|---|---|
| Calliditas Therapeutics US Inc. | 3 | $97 |
| Novo Nordisk Inc | 4 | $77 |
| Travere Therapeutics, Inc. | 5 | $72 |
| Lilly USA, LLC | 2 | $47 |
| Bayer Healthcare Pharmaceuticals Inc. | 3 | $42 |
| SHIELD THERAPEUTICS INC | 2 | $33 |
| Ardelyx, Inc. | 1 | $23 |
| AKEBIA THERAPEUTICS INC | 1 | $22 |
| Mallinckrodt Hospital Products Inc. | 1 | $21 |
| NxStage Medical, Inc. | 1 | $20 |
Products named: TARPEYO, Ozempic, MOUNJARO, Kerendia, ACCRUFER, IBSRELA, Vafseo, ACTHAR.
Industry payments across KS — which companies pay providers there.
